Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cadence Builds Case For Branded IV Acetaminophen; Can It Reduce Opioid Use?

Executive Summary

After rebounding from regulatory setbacks, Cadence Pharmaceuticals Inc. intravenous acetaminophen Ofirmev has been approved by FDA with a label many analysts praise as broad and positive.

You may also be interested in...



Opioid-Sparing Claims Should Meet High Bar, US FDA Panel Says

At meeting on Pacira's Exparel, advisory committee members warn against rushing to adopt products purported to reduce opioid consumption absent long-term longitudinal data showing beneficial public health impacts and clinical data linking reduced opioid use to functional outcomes or other clinical benefit.

Mallinckrodt Vision For Growth Emphasizes Acthar, Ofirmev

The specialty pharma laid out plans for driving future growth after completing two acquisitions earlier this year. Two of the key drivers will be drugs acquired in those deals – along with more business development.

Deals Of The Week: UCSF Catalyzes R&D Tech-Transfer Deals With Private Sector

Through the Catalyst Awards program at its Clinical and Translational Science Institute, UCSF will give MedImmune access to a broad range of discovery and preclinical opportunities under a three-year agreement. Plus, Mallinckrodt buys Cadence, Debiopharm acquires Affinium’s antibiotics program, and more.

Related Content

Topics

UsernamePublicRestriction

Register

PS052796

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel